...
首页> 外文期刊>BMC Biochemistry >Phosphatidylcholine formation by LPCAT1 is regulated by Ca 2+ and the redox status of the cell
【24h】

Phosphatidylcholine formation by LPCAT1 is regulated by Ca 2+ and the redox status of the cell

机译:LPCAT1形成的磷脂酰胆碱受Ca 2+和细胞氧化还原状态的调节

获取原文
           

摘要

Unsaturated fatty acids are susceptible to oxidation and damaged chains are removed from glycerophospholipids by phospholipase A2. De-acylated lipids are then re-acylated by lysophospholipid acyltransferase enzymes such as LPCAT1 which catalyses the formation of phosphatidylcholine (PC) from lysoPC and long-chain acyl-CoA. Activity of LPCAT1 is inhibited by Ca2+, and a Ca2+-binding motif of the EF-hand type, EFh-1, was identified in the carboxyl-terminal domain of the protein. The residues Asp-392 and Glu-403 define the loop of the hairpin structure formed by EFh-1. Substitution of D392 and E403 to alanine rendered an enzyme insensitive to Ca2+, which established that Ca2+ binding to that region negatively regulates the activity of the acyltransferase amino-terminal domain. Residue Cys-211 of the conserved motif III is not essential for catalysis and not sufficient for sensitivity to treatment by sulfhydryl-modifier agents. Among the several active cysteine-substitution mutants of LPCAT1 generated, we identified one to be resistant to treatment by sulfhydryl-alkylating and sulfhydryl-oxidizer agents. Mutant forms of LPCAT1 that are not inhibited by Ca2+ and sulfhydryl-alkylating and –oxidizing agents will provide a better understanding of the physiological function of a mechanism that places the formation of PC, and the disposal of the bioactive species lysoPC, under the control of the redox status and Ca2+ concentration of the cell.
机译:不饱和脂肪酸易于氧化,磷脂酶A2可从甘油磷脂中去除受损的链。然后通过溶血磷脂酰基转移酶(例如LPCAT1)将被去酰基化的脂质再酰基化,该酶催化lysoPC和长链酰基辅酶A形成磷脂酰胆碱(PC)。 LPCAT1的活性受到Ca2 +的抑制,并且在蛋白质的羧基末端结构域中发现了EF手型的Ca2 +结合基序EFh-1。残基Asp-392和Glu-403定义了由EFh-1形成的发夹结构的环。 D392和E403替换为丙氨酸会导致一种对Ca2 +不敏感的酶,这表明Ca2 +与该区域的结合会负面地调节酰基转移酶氨基末端结构域的活性。保守基序III的残基Cys-211对于催化不是必需的,并且不足以对巯基修饰剂对处理的敏感性。在生成的LPCAT1的几个活性半胱氨酸替代突变体中,我们确定了一个对巯基烷基化和巯基氧化剂治疗具有抗性的突变体。不受Ca2 +和巯基烷基化和-氧化剂抑制的LPCAT1突变体形式,将使人们更好地理解将PC的形成和生物活性物质lysoPC的处置置于HPLC控制下的机制的生理功能。细胞的氧化还原状态和Ca2 +浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号